Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Rationale: Cancer immunotherapy combining immune checkpoint blockade (ICB) with chemotherapeutic drugs has provided significant clinical advances. However, such combination therapeutic regimen has suffered from severe toxicity of both drugs and low response rate of patients. In this study, we propos...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Yujeong, Shim, Man Kyu, Choi, Jiwoong, Yang, Suah, Kim, Jinseong, Yun, Wan Su, Cho, Hanhee, Park, Jung Yeon, Kim, Yongju, Seong, Joon-Kyung, Kim, Kwangmeyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899589/
https://www.ncbi.nlm.nih.gov/pubmed/35265195
http://dx.doi.org/10.7150/thno.69119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899589/
https://www.ncbi.nlm.nih.gov/pubmed/35265195
http://dx.doi.org/10.7150/thno.69119

Ejemplares similares